澳研究出黑色素瘤新疗法

2012-10-09 王小舒 新华网

  澳大利亚皇家墨尔本理工大学的研究人员8日说,他们研制的一种肽能杀死黑色素瘤细胞,将来有望以此为基础开发一种专门治疗皮肤癌的乳霜。   研究人员将这种肽(即氨基酸短链)设计成能模仿黏液瘤病毒蛋白质的活动。此前的研究已表明,黏液瘤病毒能杀灭恶性黑色素瘤细胞。研究人员测试了这种肽的有效性,结果显示,它可以杀灭黑色素瘤细胞而不伤害正常的人类皮肤细胞。   恶性黑色素瘤是致死率最高的皮肤癌。“澳大利

  澳大利亚皇家墨尔本理工大学的研究人员8日说,他们研制的一种肽能杀死黑色素瘤细胞,将来有望以此为基础开发一种专门治疗皮肤癌的乳霜。

  研究人员将这种肽(即氨基酸短链)设计成能模仿黏液瘤病毒蛋白质的活动。此前的研究已表明,黏液瘤病毒能杀灭恶性黑色素瘤细胞。研究人员测试了这种肽的有效性,结果显示,它可以杀灭黑色素瘤细胞而不伤害正常的人类皮肤细胞。

  恶性黑色素瘤是致死率最高的皮肤癌。“澳大利亚的黑色素瘤发病率是世界最高的,每年超过1.1万例,”首席研究员塔格丽德·伊斯蒂万博士在声明中说。

  目前,治疗恶性黑色素瘤唯一有效的方法是早期诊断,并通过外科手术切除肿瘤及周边可能病变的健康皮肤。研究人员希望随着这项研究的深入,能研发出一种简单有效的治疗黑色素瘤的乳霜。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680215, encodeId=eadd16802151c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Dec 04 22:51:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554413, encodeId=47ab155441395, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558634, encodeId=1798155863487, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564643, encodeId=9e151564643c4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=)]
    2012-12-04 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680215, encodeId=eadd16802151c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Dec 04 22:51:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554413, encodeId=47ab155441395, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558634, encodeId=1798155863487, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564643, encodeId=9e151564643c4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=)]
    2012-10-11 kcb074
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680215, encodeId=eadd16802151c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Dec 04 22:51:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554413, encodeId=47ab155441395, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558634, encodeId=1798155863487, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564643, encodeId=9e151564643c4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680215, encodeId=eadd16802151c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Dec 04 22:51:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554413, encodeId=47ab155441395, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558634, encodeId=1798155863487, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564643, encodeId=9e151564643c4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Thu Oct 11 01:51:00 CST 2012, time=2012-10-11, status=1, ipAttribution=)]

相关资讯

Nature:癌症逃避药物治疗之谜

       癌症最可怕的特点之一就是在治疗后能够复发。对于许多类型的癌症,包括称之为黑色素瘤的皮肤癌,个体化药物能够在实验室中根除癌细胞,然而在患者体内却只生成局部的暂时的反应。长期以来癌症研究领域急待解析的一个问题就是:癌症是如何逃避药物治疗的?        来自博德研究所、达纳法伯癌症研究所和麻省总医院的

PLoS ONE:古老药用植物抑制黑色素瘤转移

近日,Gary Goldberg博士带领的国际科学家小组发现,来源于植物种子的种蛋白质可阻止黑色素瘤的蔓延,黑色素瘤是一种致命皮肤癌。据国家癌症研究所估计,今年在美国,黑色素瘤将导致超过9000人死亡。 此前发表的研究中,Goldberg博士的研究小组探究了原产于亚洲部分地区的豆科植物树的种子中提取的一种蛋白质。在中国,此树的药用价值可以追溯到400多年的古文件。Goldberg博士和他的同事发

J Invest Dermatol:抑制GSK3β阻断黑色素瘤细胞转移

糖原合成酶激酶-3(glycogen synthase kinase-3,GSK-3)是一种多功能的丝氨酸/苏氨酸蛋白激酶,是细胞内多种信号转导通路中的重要成分,不仅参与细胞内糖代谢过程而且还参与细胞增殖、细胞分化和细胞凋亡等多种重要生理过程。 一项最新研究主要集中于分析糖原合酶激酶(GSK)-3β信号在黑色素瘤中的作用。免疫组化染色显示在原位和转移性黑色素瘤组织中GSK3β的表达分别为12和3

Nat Cell Biol:黑色素瘤致病因子Sox10或有助于恶性胎记的治疗

最新的《自然—细胞生物学》Nature Cell Biology上刊登一项研究称,科学家发现了一种因子,与先天性巨痣及其引起的黑色素瘤等出生胎记的形成和存在有着密切联系。该发现或能有助于开发针对恶性胎记的治疗新方法。 Olga Shakhova, Lukas Sommer等人对患有黑色素瘤的小鼠模型进行研究,该小鼠的黑色素瘤中含有已知的突变促进因子Nras,但缺少INK4a这种在人体黑色素瘤中并

JID:蛋白Wnt1抑制皮肤癌转移

黑色素瘤的危险在于它们在非常早期的阶段促进新的淋巴管产生,并且因此能够很早地产生转移性肿瘤。故此,找到抑制淋巴管生成(lymphangiogenesis)的蛋白是至关重要的。在这项研究中,来自奥地利维也纳医科大学皮肤科的Heide Niederleithner和同事们如今证实就恶性黑色素瘤而言,Wnt1是一种能够抑制淋巴管生成和转移性肿瘤形成的蛋白。 临床前研究表明增加信号蛋白Wnt1释放抑制新

Br J Cancer:miRNA差异表达可能用于黑色素瘤的诊断或预后指标

恶性黑色素瘤的发病率正在逐年上升,并且其上升速度比任何其他癌症都要快。皮肤切除活检仍然是黑色素瘤诊断和预后判断的标准方法。良性和恶性病变组织之间有显著的形态重叠,肿瘤的厚度并不总是一个准确的预测指标。 因此确定新的分子标记物以支持组织学检查非常有必要,近日研究人员对不同病理阶段的福尔马林固定、石蜡包埋的样本进行微陈列分析,以便识别差异表达的微小RNA(miRNA)。相关研究论文发表在Britis